John Raemaekers
About
John Raemaekers is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, John Raemaekers has authored 117 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pathology and Forensic Medicine, 45 papers in Oncology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Raemaekers's work include Lymphoma Diagnosis and Treatment (75 papers), Lung Cancer Treatments and Mutations (28 papers) and Chronic Lymphocytic Leukemia Research (16 papers). John Raemaekers is often cited by papers focused on Lymphoma Diagnosis and Treatment (75 papers), Lung Cancer Treatments and Mutations (28 papers) and Chronic Lymphocytic Leukemia Research (16 papers). John Raemaekers collaborates with scholars based in Netherlands, Belgium and France. John Raemaekers's co-authors include Berthe M.P. Aleman, Jules P.P. Meijerink, Augustinus D. G. Krol, Anton Hagenbeek, Patrice Carde, Flora E. van Leeuwen, Caroline M.P.W. Mandigers, Michael Schaapveld, Frederika A. van Nimwegen and Evelyn Tönnissen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
John Raemaekers
112 papers receiving 3.7k citations
Hit Papers
Peers
John Raemaekers
Byron M. Espina United States
Dennis A. Eichenauer Germany
M. Hayat France
Kikkeri N. Naresh United Kingdom
Carol S. Portlock United States
Georg Heß Germany
Alessandro Pulsoni Italy
Dominique Cazals‐Hatem France
Mitsuyoshi Hirokawa Japan
Kieron Dunleavy United States
Citations per year, relative to John Raemaekers John Raemaekers (= 1×)
peers
Byron M. Espina
Countries citing papers authored by John Raemaekers
Since
Specialization
Citations
This map shows the geographic impact of John Raemaekers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Raemaekers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Raemaekers more than expected).
Fields of papers citing papers by John Raemaekers
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John Raemaekers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Raemaekers. The network helps show where John Raemaekers may publish in the future.
Co-authorship network of co-authors of John Raemaekers
This figure shows the co-authorship network connecting the top 25 collaborators of John Raemaekers. A scholar is included among the top collaborators of John Raemaekers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Raemaekers. John Raemaekers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kiciński, Michal, Marleen A. E. van der Kaaij, Francesco Giusti, et al.. (2022). Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials. Journal of Cancer Survivorship. 18(3). 727–738.
2.
Rodday, Angie Mae, Susan K. Parsons, Ranjana H. Advani, et al.. (2020). Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood. 136(Supplement 1). 16–18.
3.
Sasse, Stephanie, Horst Müller, Lenka Šmardová, et al.. (2015). Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leukemia & lymphoma. 57(5). 1067–1073.
4.
Stevens, Wendy B.C., J. Han van Krieken, Roel Mus, et al.. (2012). Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. Annals of Oncology. 23(10). 2676–2681.
5.
Kaaij, Marleen A. E. van der, Natacha Heutte, Jannie van Echten‐Arends, et al.. (2009). Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 94(12). 1691–1697.
6.
Hebeda, Konnie M., Marianne Linkels, Johanna M. M. Grefte, et al.. (2008). Protein Profiling of B‐Cell Lymphomas Using Tissue Biopsies: A Potential Tool for Small Samples in Pathology. Analytical Cellular Pathology. 30(1). 27–38.
7.
Glas, Annuska M., Laurent Knoops, Leonie Delahaye, et al.. (2007). Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma. Journal of Clinical Oncology. 25(4). 390–398.
8.
Noordijk, Evert M., Patrice Carde, N. Dupouy, et al.. (2006). Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. Journal of Clinical Oncology. 24(19). 3128–3135.
9.
Eghbali, Houchingue, et al.. (2005). The EORTC strategy in the treatment of Hodgkin's lymphoma. European Journal Of Haematology. 75(s66). 135–140.
10.
Raemaekers, John, Hanneke C. Kluin‐Nelemans, Ivana Teodorović, et al.. (2002). The achievements of the EORTC Lymphoma Group. European Journal of Cancer. 38. 107–113.
11.
Postema, Ernst J., Otto C. Boerman, Wim J.G. Oyen, John Raemaekers, & Frans H.M. Corstens. (2001). Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 28(11). 1725–1735.
12.
Hagenbeek, Anton, Patrice Carde, J.H. Meerwaldt, et al.. (1998). Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.. Journal of Clinical Oncology. 16(1). 41–47.
13.
Kullberg, Bart Jan, et al.. (1997). REGULATION OF THE PRODUCTION OF PRO-INFLAMMATORY CYTOKINES AND ANTAGONISTS DURING CHEMOTHERAPY-INDUCED NEUTROPENIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES. Cytokine. 9(9). 702–710.
14.
Raemaekers, John, et al.. (1995). Two hours iv infusion of 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukemia (HCL) is effective and may produce less CD34/CD8 ratio impairment. Results from the HOVON-23 study. Blood. 86.
15.
Pauw, B.E. de, John Raemaekers, J. Peter Donnelly, Bart Jan Kullberg, & Jacques F. Meis. (1995). An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology. 70(2). 83–87.
16.
Meijerink, Jules P.P., John Raemaekers, & E. J. B. M. Mensink. (1995). New type of t(14; 18) in a non‐Hodgkin's lymphoma provides insight in molecular events in early B‐cell differentiation. British Journal of Haematology. 91(3). 630–639.
17.
Koopmans, P.P., et al.. (1993). Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. European Journal of Cancer. 29(4). 515–518.
18.
Bodis, Stephan, M. Henry‐Amar, J. Bosq, et al.. (1993). Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols.. Journal of Clinical Oncology. 11(2). 225–232.
19.
Beex, L.V.A.M., et al.. (1990). Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer. A contribution to the biology and natural history of carcinoma of the female breast. Cancer. 66(6). 1165–1167.
20.
Beex, L.V.A.M., Marius MacKenzie, John Raemaekers, et al.. (1988). Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. European Journal of Cancer and Clinical Oncology. 24(4). 719–721.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Byron M. Espina Breakdown of academic impact, for papers by Dennis A. Eichenauer Breakdown of academic impact, for papers by M. Hayat Breakdown of academic impact, for papers by Kikkeri N. Naresh Breakdown of academic impact, for papers by Carol S. Portlock Breakdown of academic impact, for papers by Georg Heß Breakdown of academic impact, for papers by Alessandro Pulsoni Breakdown of academic impact, for papers by Dominique Cazals‐Hatem Breakdown of academic impact, for papers by Mitsuyoshi Hirokawa Breakdown of academic impact, for papers by Kieron Dunleavy